Phase I/II study of a novel peptide vaccination therapy, CDCA1 and KOC1, for previously treated advanced non-small-cell lung cancer
Phase 1
Completed
- Conditions
- previously treated advanced non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000005087
- Lead Sponsor
- Showa University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded if they have already received vaccination therapy, they had severe heart disease, active infection, severe drug allergy, other serious underlying medical conditions, symptomatic brain metastasis, or an active second malignancy, and they received steroids or immunosuppressing agent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie CDCA1 and KOC1 peptide vaccine efficacy in advanced NSCLC?
How does CDCA1/KOC1 peptide vaccination compare to standard immunotherapies for previously treated NSCLC?
Which biomarkers correlate with response to CDCA1 and KOC1 vaccines in non-small-cell lung cancer?
What adverse events are associated with CDCA1 and KOC1 peptide therapy in phase I NSCLC trials?
Are there combination therapies with CDCA1/KOC1 peptides showing enhanced efficacy in advanced NSCLC?